Blog Category

Press Releases

Biophytis Announces New Cash Contribution and Debt Conversion up to €8.6 million to Finance the Obesity Program

, , ,

/

8 January 2025

Biophytis announces temporary suspension of the listing of its shares and share warrants prior to the completion of a refinancing transaction

,

/

6 January 2025

Biophytis Will Be In San Franscico During The 2025 JP Morgan Healthcare Conference

,

/

24 December 2024

Biophytis showcased the OBA program in obesity at the 17th SCWD international congress

,

/

23 December 2024

Biophytis participates in the 17th SCWD Congress and hosts an Obesity Investor Call

,

/

2 December 2024

Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities

, , ,

/

30 September 2024

Presentation of Prof. Capucine Morelot-Panzini on 20E (BIO101) for Severe COVID-19 at the ERS 2024 Conference in Vienna

,

/

25 September 2024

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia

,

/

22 July 2024

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity

, , ,

/

11 July 2024

JULY 1st, 2024

,

/

1 July 2024

RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024

,

/

25 June 2024

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens

,

/

12 June 2024